免疫检查点抑制剂治疗原发性肝癌生物标志物的研究进展  

Research progress of immune checkpoint inhibitors in the treatment of primary liver cancer biomarkers

作　　者：张丽[1] 白玉贤[1] ZHANG Li;BAI Yuxian(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2024年第11期2125-2129,共5页Journal of Modern Oncology

摘　　要：免疫检查点抑制剂已成为原发性肝癌的一种有前景的治疗策略。但是,持久的反应和良好的长期疗效也仅限于一小部分患者。寻找有效的生物标志物来预测免疫检查点抑制剂治疗原发性肝癌的疗效有重要的指导价值。该文将概述生物标志物在原发性肝癌免疫治疗中的最新研究进展。Immune checkpoint inhibitors have become a promising treatment strategy for primary liver cancer.However,durable responses and good long-term outcomes are limited to a small proportion of patients.It is important to find effective biomarkers to predict the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer.This article will summarize the latest research progress of biomarkers in immunotherapy for primary liver cancer.

关 键 词：原发性肝癌 免疫检查点抑制剂 生物标志物 

分 类 号：R735.7[医药卫生—肿瘤]